39.34

4.42% -1.82

After Hours: 39.34

Edgewise Therapeutics Inc (EWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Edgewise Therapeutics Inc stock is traded at $39.34, with a volume of 1.77M. It is down -4.42% in the last 24 hours and down -11.02% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Previous Close:

$41.16

Open:

$41.59

24h Volume:

1.77M

Relative Volume:

1.41

Market Cap:

$4.27B

Revenue:

Net Income/Loss:

$-176.01M

P/E Ratio:

-23.68

EPS:

-1.661

Net Cash Flow:

$-148.97M

1W Performance:

-13.20%

1M Performance:

-11.02%

6M Performance:

+23.17%

1Y Performance:

+164.29%

1-Day Range:

$38.57

$41.99

1-Week Range:

$38.57

$45.99

52-Week Range:

$14.25

$48.51

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name

Edgewise Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

720-262-7002

Address

1715 38TH ST, BOULDER

Employee

154

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

EWTX's Discussions on Twitter

Compare EWTX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EWTX Edgewise Therapeutics Inc	39.34	4.27B	0	-176.01M	-148.97M	-1.661
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-25-25	Initiated	Goldman	Neutral
Jul-30-25	Initiated	Raymond James	Strong Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Apr-30-25	Initiated	Guggenheim	Buy
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Jan-22-25	Initiated	Stifel	Hold
Nov-22-24	Initiated	Evercore ISI	Outperform
Mar-07-24	Initiated	Piper Sandler	Overweight
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell
Apr-13-22	Initiated	RBC Capital Mkts	Outperform
Jan-28-22	Initiated	Goldman	Neutral

View All

Edgewise Therapeutics Inc Stock (EWTX) Latest News

Sep 25, 2026

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says - marketscreener.com

Sep 25, 2026

Sep 23, 2026

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says - marketscreener.com

Sep 23, 2026

H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57 - Moomoo

Sep 23, 2026

Sep 22, 2026